Clinical development of fulvestrant ('Faslodex')

Cancer Treatment Reviews

Volumn 31, Issue SUPPL. 2, 2005, Pages

  Howell, Anthony ^a   Abram, Paul ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

'Faslodex'; Advanced breast cancer; Aromatase inhibitors; Clinical trials; Fulvestrant; Gefitinib; Long term oestrogen deprivation; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ARZOXIFENE; CONTRACEPTIVE AGENT; CYTOTOXIC AGENT; DIETHYLSTILBESTROL; DROLOXIFENE; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; EXEMESTANE; FULVESTRANT; HORMONE RECEPTOR; IDOXIFENE; LIPID; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PIPENDOXIFENE; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHROPATHY; ARTICLE; BODY WEIGHT DISORDER; BONE DENSITY; BRAIN FUNCTION; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HOT FLUSH; HUMAN; INJECTION SITE REACTION; LIPID BLOOD LEVEL; LUNG EMBOLISM; MEDICAL RESEARCH; NONHUMAN; POSTMENOPAUSE; THROMBOEMBOLISM; URINARY TRACT INFECTION; VAGINITIS; WEIGHT GAIN;

AGED; BREAST NEOPLASMS; CLINICAL TRIALS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 27144439204     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.08.010     Document Type: Article

References (43)

1. G.T. Beatson On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases Lancet 2 1896 105-107
2. E.C. Dodds L. Golberg W. Lawson R. Robinson Oestrogenic activity of certain synthetic compounds Nature 141 1938 247-248
3. S. Schrager B.E. Potter Diethylstilbestrol exposure Am Fam Physician 69 2004 2395-2400
4. P.E. Lonning P.D. Taylor G. Anker et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy Breast Cancer Res Treat 67 2001 111-116
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials Lancet 351 1998 1451-1467
6. M. Hasmann B. Rattel R. Loser Preclinical data for droloxifene Cancer Lett 84 1994 101-116
7. S.R. Johnston S. Riddler B.P. Haynes The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance Br J Cancer 75 1997 804-809
8. S.P. Robinson C.J. Parker V.C. Jordan Preclinical studies with toremifene as an antitumor agent Breast Cancer Res Treat 16 Suppl. 1990 S9-S17
9. L.E. Stenbygaard J. Herrstedt J.F. Thomsen K.R. Svendsen S.A. Engelholm P. Dombernowsky Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial Breast Cancer Res Treat 25 1993 57-63
10. A. Buzdar D. Hayes Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer Breast Cancer Res Treat 73 2002 161-175
11. E.S. Lee J.M. Schafer K. Yao et al. Cross resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice Clin Cancer Res 6 2000 4893-4899
12. K. Holli R. Valavaara G. Blanco Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group J Clin Oncol 18 2000 3487-3494
13. M.B. Marttunen P. Hietanen A. Tiitinen O. Ylikorkala Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients J Clin Endocrinol Metab 83 1998 1158-1162
14. M.B. Marttunen B. Cacciatore P. Hietanen et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women Br J Cancer 84 2001 897-902
15. W.J. Gradishar J.E. Glusman C. Vogel et al. Raloxifene HCI, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer Breast Cancer Res Treat 20 Suppl. 1997 53 [abstract 209]
16. P.N. Munster A. Buzdar K. Dhingra et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer J Clin Oncol 19 2001 2002-2009
17. M.M. Cotreau L. Stonis K.H. Dykstra et al. Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women J Clin Pharmacol 42 2002 157-165
18. A.E. Wakeling J. Bowler Steroidal pure antioestrogens J Endocrinol 112 1987 R7-R10
19. A.E. Wakeling M. Dukes J. Bowler A potent specific pure antiestrogen with clinical potential Cancer Res 51 1991 3867-3873
20. C.K. Osborne Steroid hormone receptors in breast cancer management Breast Cancer Res Treat 51 1998 227-238
21. X.F. Hu M. Veroni M. De Luise et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780 Int J Cancer 55 1993 873-876
22. R.A. McClelland J.M. Gee A.B. Francis Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer Eur J Cancer A 32 1996 413-416
23. R.I. Nicholson J.M. Gee A.B. Francis D.L. Manning A.E. Wakeling B.S. Katzenellenbogen Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells Endocr Relat Cancer 2 1995 115-121
24. V. Muller E.V. Jensen C. Knabbe Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines Cancer Res 58 1998 263-267
25. C.K. Osborne M. Jarman R. McCague E.B. Coronado S.G. Hilsenbeck A.E. Wakeling The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth Cancer Chemother Pharmacol 34 1994 89-95
26. J.F. Robertson R.I. Nicholson N.J. Bundred Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer Cancer Res 61 2001 6739-6746
27. M. Dukes J.C. Waterton A.E. Wakeling Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): Quantitative magnetic resonance imaging J Endocrinol 138 1993 203-210
28. S. Addo R.A. Yates A. Laight A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers Br J Cancer 87 2002 1354-1359
29. A. Howell C.K. Osborne C. Morris A.E. Wakeling ICI 182,780 (Faslodex™): Development of a novel, "pure" antiestrogen Cancer 89 2000 817-825
30. A. Howell D.J. DeFriend J.F. Robertson et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer Br J Cancer 74 1996 300-308
31. S.G. Lundeen J.M. Carver M.-L. McKean R.C. Winneker Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels Endocrinology 138 1997 1552-1558
32. G.N. Wade J.D. Blaustein J.M. Gray J.M. Meredith ICI 182,780: A pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain Am J Physiol 265 6 Pt 2 1993 R1392-R1398
33. J.F. Robertson C.K. Osborne A. Howell et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials Cancer 98 2003 229-238
34. L. Mauriac J.E. Pippen J. Quaresma Albano S.Z. Gertler C.K. Osborne Fulvestr ant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials Eur J Cancer 39 2003 1228-1233
35. A. Howell J. Pippen R. Elledge et al. Fulvestrant versus anastrozole for the treatment of advanced breast cancer: A prospectively planned combined survival analysis of two multicenter trials Cancer 104 2005 236-239
36. A. Howell J.F.R. Robertson P. Abram et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial J Clin Oncol 22 2004 1605-1613
37. L. Perey R. Paridaens F. Nolé Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: Update of a phase II SAKK trial Breast Cancer Res Treat 88 Suppl. 1 2004 S236 [abstract 6048]
38. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group. In: Poster presentation at the San Antonio breast cancer symposium, 8-11 December, San Antonio, TX, USA; 2004 [poster 409].
39. J.N. Ingle K.M. Rowland V.J. Suman et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group Breast Cancer Res Treat 88 Suppl. 1 2004 S38 [abstract 409]
40. J.F.R. Robertson A. Howell V.A. Gorbunova T. Watanabe T. Pienkowski M.R. Lichinitser Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant Breast Cancer Res Treat 92 2005 169-174
41. I. Vergote J.F.R. Robertson U. Kleeberg G. Burton C.K. Osborne L. Mauriac Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy Breast Cancer Res Treat 79 2003 207-211
42. R. Paridaens L. Dirix C. Lohrisch et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann Oncol 14 2003 1391-1398
43. M. Kaufmann E. Bajetta L.Y. Dirix et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group J Clin Oncol 18 2000 1399-1411